Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease

Diabetes and Metabolism

Volumn 25, Issue 5, 1999, Pages 383-392

  Vigouroux, C ^b   Gharakhanian, S ^b   Salhi, Y ^b   Nguyen T H ^b   Adda, N ^b   Rozenbaum, W ^b   Capeau, J ^a,b  

^a INSERM   (France)

^b HÔPITAL ROTHSCHILD   (France)

Author keywords

Dyslipidaemia; Insulin resistance; Lipodystrophy; NRTI; Protease inhibitors

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; REVIEW;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INSULIN RESISTANCE; METABOLIC DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0032707973     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med, 1997, 337, 725-733.
2. Flexner C. HIV-protease inhibitors. N Engl J Med, 1998, 338, 1281-1292.
3. Pettit R, Muurahainen N, Falutz J et al. HIV-related truncal obesity : a comparison of physician and patient diagnoses in the SALSA (Self-Ascertained Lipodystrophy Syndrome Assessment) questionnaire [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 651.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Diagnosis and prediction of HIV protease inhibitor (PI)-induced lipodystrophy and impaired glucose tolerance [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 641.
5. Romeu J, Bonjoch A, Amo A et al. Lipodystrophy index by anthropometric parameters (LIAP) : an approach to the diagnosis of lipodystrophy by measurable parameters in patients taking protease inhibitors [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 652.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus : a cohort study. Lancet, 1999, 353, 2093-2099.
7. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998, 12, F51-F58.
8. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS, 1998, 12, F37-F39.
9. Hellerstein MK, Grunfeld C, Wu K et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab, 1993, 76, 559-565.
10. Lo JC, Mulligan K, Tai VW, Heather A, Schambelan M. « Buffalo hump » in men with HIV-1 infection. Lancet, 1997, 351, 867-870.
11. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet, 1997, 350, 1596.
12. Miller KK, Daly PA, Sentochnik D et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clinical Infectious Disease, 1998, 27, 68-72.
13. Aboulafia DM, Bundow D. Images in clinical medicine. Buffalo hump in a patient with the acquired immunodeficiency syndrome. N Engl J Med, 1998, 339, 1297.
14. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral-fat accumulation associated with use of indinavir. Lancet, 1998, 351, 871-875.
15. Gervasoni C, Ridolfo AL, Trifiro G et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS, 1999, 13, 465-471.
16. Sutinen J, Mathur-Wagh U. Changes in body shape during PI therapy in HIV+ women [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 662.
17. Falutz J. Gender related differences in the lipodystrophy syndrome [Abstract]. Third International Conference on Nutrition and HIV Infection, Cannes, France, April 1999, S3-O4.
18. Kotler DP. Body composition in HIV infection : then and now [Abstract]. Third International Conference on Nutrition and HIV Infection, Cannes, France, April 1999, S4-6.
19. Saint-Marc T, Poizot-Martin I, Partisani M, Fabre J, Touraine J. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 653.
20. Madge S, Kinloch-De Loes S, Tyrer M, Johnson M. Lipodystrophy syndrome in patients on reverse transcriptase inhibitors [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 654.
21. Galli M, Ridolfo AL, Gervasoni C, Ravasio I, Adomi F, Moroni M. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations [Abstract]. Antiviral Therapy, 1999, 4 (suppl2), 29.
22. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy : contribution to PI-related LD syndrome [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 19.
23. Albrecht H, Stellbrink HJ, Arasteh K. Didanosine-induced disorders of glucose tolerance. Ann Intern Med, 1993, 119, 1050.
24. Vittecoq D, Zucman D, Auperin I, Passeron J. Transient insulin-dependent diabetes mellitus in an HIV-infected patient receiving didanosine. AIDS, 1994, 8, 1351.
25. Chidiac C, Alfandari S, Caron J, Mouton Y. Diabetes mellitus following treatment of AIDS with didanosine, AIDS, 1995, 9, 215-216.
26. Assan R, Perronne C, Assan D et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care, 1995, 18, 47-55.
27. Salinas I, Lucas A, Clotet B. Secondary diabetes induced by megestrol acetate therapy in a patient with AIDS-associated cachexia. AIDS, 1993, 7, 894.
28. Henry K, Rathgaber S, Sullivan C, McCabe K. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med, 1992, 116, 53-54.
29. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory, 1997, June 11.
30. Ault A. FDA warns of potential protease-inhibitor link to hyperglycaemia. Lancet, 1997, 349, 1819.
31. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycemia. Lancet, 1997, 350, 713-714.
32. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med, 1997, 127, 947.
33. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med, 1997, 127, 948.
34. Meyer L, Rabaud C, Ziegler O, May T, Drouin P. Protease inhibitors, diabetes mellitus and blood lipids. Diabetes Metab, 1998, 24, 547-549.
35. Martinez E, Casamitjana R, Conget I, Gatell JM. Protease inhibitor-associated hyperinsulinaemia. AIDS, 1998, 12, 2077-2079.
36. Walli R, Herfort O, Michi GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS, 1998, 12, F167-F173.
37. Vigouroux C, Gharakhanian S, Salhi Y et al. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab, 1999, 25, 225-232.
38. Rozenbaum W, Gharakhanian S, Salhi Y et al. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 20.
39. Grunfeld C, Kotler DP, Hamadeh R, Tiemey A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med, 1989, 86, 27-31.
40. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab, 1992, 74, 1045-1552.
41. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS, 1998, 12, 1393-1394.
42. Schambelan M. Syndromes of fat redistribution [Abstract]. Third International Conference on Nutrition and HIV Infection, Cannes, France, April 1999, S6-11.
43. Martinez E, Gatell JM. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients : the lipodystrophy syndrome. Curr Opin Infect Dis, 1999, 12, 13-19.
44. Poizot-Martin I, Saint-Marc T, Thirion X et al. Cross-sectional and longitudinal evaluation of body composition in HIV infected patients [Abstract]. Third International Conference on Nutrition and HIV Infection, Cannes, France, April 1999, S3-05.
45. Walli R. HAART-associated insulin resistance : possible mechanisms and therapeutical strategies [Abstract]. Third International Conference on Nutrition and HIV Infection, Cannes, France, April 1999, S9-20.
46. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med, 1991, 325, 938-948.
47. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl, 1996, 413, 2-28.
48. Vigouroux C, Khallouf E, Bourut C et al. Genetic exclusion of fourteen candidate genes in lipoatrophic diabetes using linkage analysis in ten consanguineous families. J Clin Endocrinol Metab, 1997, 82, 3438-3444.
49. Moitra J, Mason MM, Olive M et al. Life without white fat : a transgenic mouse. Genes Dev, 1998, 12, 3168-3181.
50. Shimomura I, Hammer RE, Richardson JA et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue : model for congenital generalized lipodystrophy. Genes Dev, 1998, 12, 3182-3194.
51. Ursich MJM, Fukui RT, Galvao MSA et al. Insulin resistance in limb and trunk partial lipodyqtrophy (type 2 Köbberling-Dunnigan syndrome). Metabolism, 1997, 46, 159-163.
52. Peters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet, 1998, 18, 292-295.
53. Marin P, Andersson B, Ottosson M et al. The morphology and metabolism ofintraabdominal adipose tissue in men. Metabolism, 1992, 41, 1242-1248.
54. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med, 1995, 27, 435-438.
55. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest, 1998, 101, 1354-1361.
56. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 1999, 22, 288-293.
57. Arioglu E, Duncan Morin JL, Gottlieb N et al. Efficacy of troglitazone in the treatment of lipoatrophic diabetes : preliminary results of an ongoing study [Abstract]. Diabetes, 1999, 48 (suppl. 1), A93.
58. Lenhard J, Furfine E, Paulik M, Croom D, Spaltenstein A, Weiel J. Effect of HIV protease inhibitors on in vitro adipogenesis and in vivo fat deposition [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 3.
59. Sissons JG, West RJ, Fallows J et al. The complement abnormalities of lipodystrophy. N Engl J Med, 1976, 294, 461-465.
60. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-1607.
61. Gamez J, Playan A, Andreu AL et al. Familial multiple symmetric lipomatosis associated with the A8344G mutation of mitochondrial DNA. Neurology, 1998, 51, 258-260.
62. Klopstock T, Naumann M, Seibel P, Shaike B, Reiner K, Reichmann H. Mitochondrial DNA mutations in multiple symmetric lipomatosis. Mol Cell Biochem, 1997, 174, 271-275.
63. Brinkman K. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 15.
64. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. NRTI-induced mitochondrial toxicity as an aetiology for fat redistribution syndrome [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 41.
65. Yanovski JA, Miller KD, Kino T et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab, 1999, 84, 1925-1931.
66. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect « Cushing's disease of the omentum »? Lancet, 1997, 49, 1210-1213.
67. Renard E, Fabre J, Paris F, Reynes J, Bringer J. Developpement d'un syndrome associant obésité abdominale, lipoatrophie périphérique et hypercortisolisme chez des sujets infectés par le HIV. Ann Endocrinol, 1998, 59, A143.
68. Hirsch M, Klibanski A. What price progress? Pseudo-Cushing's syndrome associated with antiretroviral therapy in patients with human immunodeficiency virus infection. Clin Infect Dis, 1998, 27, 73-75.
69. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF α- and obesity-induced insulin resistance. Science, 1996, 277, 665-668.
70. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 1998, 351, 1881-1883.
71. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest, 1997, 100, 3149-3153.
72. Randle PJ, Garland PB, Hales CN, Newholme EA. The fatty acid cycle : its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1963, i, 785-789.
73. Stevens GJ, Chen M, Grecko R et al. Investigations into the proposed mechanisms of HIV-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance syndrome [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 34.
74. Rohlmann A, Gotthardt M, Hammer R, Herz J. Inducible Inactivation of Hepatic LRP Gene by Cre-mediated Recombination Confirms Role of LRP in Clearance of Chylomicron Remnants. J Clin Invest, 1998, 101, 689-695.
75. Gagnon A, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet, 1998, 352, 1032.
76. Lenhard J, Weiel J, Paulik M et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 666.
77. Goebel FD, Walli R. ART-associated insulin resistance : frequency, potential causes and possible therapeutic interventions [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 7.
78. Nolte LA, Yarasheski KE, Kawanaka K, Holloszy JO. HIV protease inhibitor decreases insulin-stimulated glucose transport in skeletal muscle [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 53.
79. Gilquin J, Viard JP, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves' disease after immune restoration with highly active antiretroviral therapy. Lancet, 1998, 352, 1907-1908.
80. Tsiodras S, Mantzoros C, Hammer SM, Samore M. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia : a five year analysis [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 643.
81. Justman J, Danoff A, Benning L et al. Association of diabetes and protease inhibitor use in a large natural history cohort of HIV+ women [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 661.
82. Carr A, Thorisdottir A, Samaras K, Kaufmann G, Chisholm D, Cooper D. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PI or swithching to nelfinavir [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 668.
83. Lee D, Mathews W. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 644.
84. Behrens G, Dejam A, Schmidt H, Brabant G, Stoll M, Schmidt R. Lipid evaluation and glucose metabolism in HIV-1 positive patients treated with protease inhibitors [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 647.
85. Walli R, Michi GM, Segerer S et al. Dyslipidemia and insulin resistance in HIV-infected patients treated with reverse transcriptase inhibitors alone and in combination with protease inhibitors [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 645.
86. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS, 1999, 13, 805-810.
87. Ruiz L, Negredo E, Bonjoch A et al. A multicentre, randomized, open-label, comparative trial of the clinical, immunological and virological benefit of switching the PI by nevirapine in HAART-experienced patients suffering lipodystrophy [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 35.
88. Gatell JM, Conget I, Lozano I, Casamitjana R, Martinez E. One year effects of switching from HIV-1 PIs to nevirapine on metabolic abnormalities [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 40.
89. Moyle GJ, Baldwin C, Comitis S, Dent N, Gazzard BG. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 48.
90. Rozenbaum W, Adda N, Nguyen T et al. Prospective follow-up of a PI substitution for efavirenz in patients with HIV-related lipodystrophy syndrome [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 55.
91. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet, 1998, 351, 1328.
92. Juette A, Salzberger B, Franzen C, Roemer K, Diehl V, Faetkenheuer G. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 656.
93. Klein D, Sidney S, Hurley L, Iribarren C. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 657.
94. Coplan P, Nikas A, Saah A et al. No association observed between indinavir therapy for HIV/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects [Abstract]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, abstract 658.
95. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet, 1998, 352, 1031-1032.
96. Saint-Marc T. Effects of metformin on insulin resistance and central adiposity in Pi-experienced patients [Abstract]. Third International Conference on Nutrition and HIV Infection, Cannes, France, April 1999, S9-21.
97. Grunfeld C. Dyslipidemia due to HIV infection and its therapy [Abstract]. Antiviral Therapy, 1999, 4 (suppl 2), 1.